Esperion Therapeutics (ESPR) News Today $2.48 +0.02 (+0.61%) As of 02:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Esperion Therapeutics (NASDAQ:ESPR) Earns Sell (D-) Rating from Weiss RatingsOctober 9 at 2:17 AM | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Down - Should You Sell?October 8 at 11:51 AM | marketbeat.comEsperion Announces Pricing of Public Offering of Common StockOctober 7 at 9:29 PM | globenewswire.comEsperion stock tumbles after announcing public offeringOctober 7 at 8:51 PM | investing.comEsperion Announces Proposed Public Offering of Common StockOctober 7 at 4:01 PM | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Up - Time to Buy?October 3, 2025 | marketbeat.comEsperion Shares Rally After Patent Litigation Settlement For Cholesterol DrugsOctober 3, 2025 | msn.comEsperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid ...October 3, 2025 | finance.yahoo.comEsperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040October 3, 2025 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Trading Up 8.9% - Still a Buy?October 1, 2025 | marketbeat.comHead to Head Analysis: Rafael (NYSE:RFL) vs. Esperion Therapeutics (NASDAQ:ESPR)September 29, 2025 | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Raised to Buy at Wall Street ZenSeptember 26, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Trading Up 6.7% - What's Next?September 25, 2025 | marketbeat.comUMB Bank n.a. Takes $167,000 Position in Esperion Therapeutics, Inc. $ESPRSeptember 24, 2025 | marketbeat.comEsperion Therapeutics, Inc. $ESPR Shares Bought by Parallel Advisors LLCSeptember 24, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Up - Still a Buy?September 20, 2025 | marketbeat.comEsperion Therapeutics' (ESPR) Buy Rating Reaffirmed at HC WainwrightSeptember 20, 2025 | marketbeat.comEsperion stock rises after Japan approves cholesterol drug NEXLETOLSeptember 19, 2025 | za.investing.comEsperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $17,547.60 in StockSeptember 19, 2025 | marketbeat.comBenjamin Halladay Sells 7,046 Shares of Esperion Therapeutics (NASDAQ:ESPR) StockSeptember 19, 2025 | marketbeat.comEsperion and Otsuka Receive Approval for NEXLETOL® in Japan for Hypercholesterolemia TreatmentSeptember 19, 2025 | quiverquant.comQEsperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of HypercholesterolemiaSeptember 19, 2025 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) General Counsel Benjamin Looker Sells 6,267 SharesSeptember 19, 2025 | insidertrades.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 19, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Trading 7.1% Higher - Here's What HappenedSeptember 13, 2025 | marketbeat.comEsperion: A Mixture Of Opportunity And Risk: Why I Would Hold For NowSeptember 9, 2025 | seekingalpha.comTwo Seas Capital LP Lowers Stock Position in Esperion Therapeutics, Inc. $ESPRSeptember 9, 2025 | marketbeat.comEsperion Therapeutics, Inc. $ESPR Stock Holdings Lifted by Invesco Ltd.September 8, 2025 | marketbeat.comEsperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comGraham Capital Management L.P. Purchases 295,320 Shares of Esperion Therapeutics, Inc. $ESPRSeptember 7, 2025 | marketbeat.comEsperion Therapeutics Target of Unusually Large Options Trading (NASDAQ:ESPR)September 4, 2025 | marketbeat.comWellington Management Group LLP Acquires 201,704 Shares of Esperion Therapeutics, Inc. $ESPRSeptember 2, 2025 | marketbeat.comEsperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of DyslipidaemiasAugust 29, 2025 | markets.businessinsider.comEsperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of DyslipidaemiasAugust 29, 2025 | globenewswire.comNuveen LLC Buys Shares of 3,087,700 Esperion Therapeutics, Inc. $ESPRAugust 29, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Lowered to "Hold" Rating by Wall Street ZenAugust 27, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 27, 2025 | marketbeat.comEsperion Therapeutics’ Earnings Call Highlights GrowthAugust 23, 2025 | theglobeandmail.comAre Options Traders Betting on a Big Move in Esperion Therapeutics Stock?August 22, 2025 | msn.comEsperion Therapeutics (NASDAQ:ESPR) Upgraded at Wall Street ZenAugust 18, 2025 | marketbeat.comHeadlands Technologies LLC Sells 216,619 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)August 14, 2025 | marketbeat.comEsperion Delays Q2 2025 Financial Report FilingAugust 11, 2025 | msn.comEsperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at Wall Street ZenAugust 10, 2025 | marketbeat.comFY2025 EPS Estimates for ESPR Increased by Cantor FitzgeraldAugust 9, 2025 | marketbeat.comHC Wainwright Has Bullish Estimate for ESPR Q3 EarningsAugust 9, 2025 | marketbeat.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 7, 2025 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Announces Quarterly Earnings ResultsAugust 6, 2025 | marketbeat.comEsperion (ESPR) Q2 Revenue Jumps 12%August 5, 2025 | fool.comEsperion rises after revenue beat, Q1 profitability expectationAugust 5, 2025 | seekingalpha.comEsperion Therapeutics, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 5, 2025 | seekingalpha.com Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.310.77▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼84▲ESPR Articles Average Week Get the Latest News and Ratings for ESPR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Belite Bio News Today Galapagos News Today Cidara Therapeutics News Today IDEAYA Biosciences News Today Disc Medicine News Today Recursion Pharmaceuticals News Today Bausch Health Cos News Today ImmunityBio News Today Agios Pharmaceuticals News Today Arcutis Biotherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsoleteWhen a new chip can run at the speed of light, the game changes. This is the reality of “TF3” — a man-made...The Oxford Club | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
